Clinical features, risk factors, and outcome of carbapenem-resistant Acinetobacter baumannii bacteremia in a Thai neonatal intensive care unit

Narongsak Nakwan 1 , 2 , Jeerawan Wannaro 2 , Narongwit Nakwan 3 , Wichian Patungkalo 4  and Kulkanya Chokephaibulkit 5
  • 1 MD, Neonatal Intensive Care Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand Thailand
  • 2 Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand
  • 3 Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand
  • 4 Division of Microbiology, Hat Yai Medical Education Center, Hat Yai Hospital, Songkhla 90110, Thailand
  • 5 Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand


Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) infection have been increasingly observed and are associated with mortality in neonatal population.

Objective: We determined risk factors for and outcome of bacteremia caused by CRAB in neonates.

Methods: The clinical data of neonates who developed A. baumannii bacteremia from January 2005 to December 2010 were retrospectively reviewed.

Results: During the study period, 22 neonates developed A. baumannii bacteremia, 13 were CRAB at an incidence of 0.5 case/1000 patients-day. Compared with carbapenem-sensitive A. baumannii (CSAB), patients with CRAB bacteremia had lower birth weight, lower gestational age and were more often receiving mechanical ventilation at the onset of bacteremia. Most of the CSAB isolates were susceptible to cefoperazone/sulbactam (89%) and aminoglycosides (50-75%). In contrast, CRAB strains were all resistant to cephalosporins, carbapenems, quinolones, with 39% susceptible to cefoperazone/sulbactam and 8% susceptible to amikacin. Most cases of CRAB bacteremia were treated with cefoperazone/sulbactam or meropenem and in some cases, with the addition of colistin. The all cause morality rates were 54% in CRAB and 11% in CSAB bacteremia, respectively (p = 0.07).

Conclusions: Neonatal bacteremia caused by A. baumannii was not common but caused high mortality, particularly from CRAB. Lack of effective antibiotics was the major challenge in treating these patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Chan PC, Huang LM, Lin HC, Chang LY, Chen ML, Lu CY. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2007; 28:423-9.

  • 2. McGrath EJ, Chopra T, Abdel-Haq N, Preney K, Koo W, Asmar BI, et al. An outbreak of carbapenemresistant Acinetobacter baumannii infection in a neonatal intensive care unit: investigation and control. Infect Control Hosp Epidemiol. 2011; 32: 34-41.

  • 3. Mittal N, Nair D, Gupta N, Rawat D, Kabra S, Kumar S, et al. Outbreak of Acinetobacter spp septicemia in a neonatal ICU. Southeast Asian J Trop Med Heath. 2003; 34:365-6.

  • 4. Huang YC, Su LH, Wu TL, Leu HS, Hsieh WS, Chang TM, et al. Outbreak of Acinetobacter baumannii bacteremia in a neonatal intensive case unit: clinical implications and genotyping analysis.

  • Pediatr Infect Dis J. 2002; 21:1105-9.

  • 5. Manzar S. Outbreak of multidrug resistant Acinetobacter in the neonatal intensive care unit.

  • Saudi Med J. 2004; 25:961-3.

  • 6. Chang PY, Hsueh PR, Wu PS, Chan PC, Yang TT, Lu CY, et al. Muldrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan. J Microbiol Immunol Infect. 2007; 40: 406-10.

  • 7. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection. 2010; 38:173-80.

    • Crossref
    • Export Citation
  • 8. Kuo LC, Yu CJ, Lee LN, Wang JL, Wang HC, Hsueh PR, et al. Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc. 2003; 102: 601-6.

  • 9. Higgins PG, Dammhayn C, Hackel M, Seifert H.

  • Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010; 65:233-8.

  • 10. Le Hello S, Falcot V, Lacassin F, Mikulski M, Baumann F. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand J Infect Dis 2010; 42:821-6.

    • Crossref
    • Export Citation
  • 11. CLSI. Performance standards for antimicrobial disk susceptibility testing: twentieth information supplement. CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

  • 12. Drews MB, Ludwig AC, Leititist JU, Daschner FD.

  • Low birth weight and nosocomial infection of neonates in a neonatal intensive care unit. J Hosp Infect. 1995; 30:65-72.

  • 13. Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control. 2002; 30:386-90.

    • Crossref
    • Export Citation
  • 14. Gaynes RP, Edwards JR, Jarvis WR, Culver DH, Tolson JS, Martone WJ. Nosocomial infections among neonates in high-risk nurseries in the United States.

  • National Nosocomial Infections Surveillance System.

  • Pediatrics. 1996; 98:357-61.

  • 15. Cohen-Wolkowiez M, Moran C, Benjamin DK, Cotten CM, Clark RH, Benjamin DK Jr, et al. Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J. 2009; 28:1052-6.

    • Crossref
    • Export Citation
  • 16. Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V. Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010; 169:867-74.

  • 17. Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report.

  • Pediatr Pulmol. 2011; 46:60-6.

  • 18. Tiengrim S, Tribuddharat C, Thamlikitkul V. In vitro activity of tigecycline against clinical isolates of multi-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. J Med Assoc Thai. 2006; 89: S102-S105.

  • 19. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008; 62:45-55.

    • Crossref
    • Export Citation

Journal + Issues